teclistamab-cqyv injection, for subcutaneous use Initial U.S. Approval: 2022

TECVAYLI (teclistamab-cqyv) injection as specified in the prescribing information, teclistamab-cqyv injection is indicated for the treatment of multiple myeloma disease. As per highlights Of prescribing information teclistamab-cqyv injection is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.

Facts about teclistamab injection

Disease Indications: Multiple Myeloma
Dosage Forms And Strengths:
Injection
• 30 mg/3 mL (10 mg/mL) in a single-dose vial
• 153 mg/1.7 mL (90 mg/mL) in a single-dose vial

Manufacturer: Janssen Biotech
Usage: Subcutaneous
Medicine Approved By: Food and Drug Administration (FDA), European Medical Agency (EMA)
(teclistamab-cqyv) injection was approved by the FDA in January 2022

Extra Information:

• www.accessdata.fda.gov
• www.ema.europa.eu

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “teclistamab injection” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.